Home
- Belegger.nl: steun en toeverlaat voor beleggers. Bekijk de beurskoersen, de laatste stand van de AEX en lees het nieuws, de columns en de adviezen.
Koersen
- Aandelen
- Indices
- Valutas
- Rentes
- Commodities
- Certificaten
- Opties
- Futures
- Beleggingsfondsen
- Trackers
- Obligaties
- Hefboomproducten
Nieuws
Forum
Analyse & advies
Thema's
- Beurstips en handelskansen
- Fondsen & ETF's

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX: Euronext Amsterdam
BRU: Euronext Brussels
PSE: Euronext Paris
LIS: Euronext Lissabon
CHX: CBOE Europe, grote(re) EU aandelen
NAV: Investment Funds (NAV)

Noord-Amerika

NYS: New York Stock Exchange
OTC: CBOE BZX Exchange (US)
TSE: Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

Market Monitor

Koffiekamer « Terug naar discussie overzicht

Omega Diagnostics Group [ODX] - Ready to Launch the Rocket

454 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 ... 19 20 21 22 23 » | Laatste

Omlaag ↓

TheBiG 15 november 2020 21:56

Ohja en mocht er nog een MHRA approval komt voor home testing is het feest helemaal compleet.

[verwijderd] 16 november 2020 07:50

Goeiemorgen, iemand die zicht heeft op het order boekje vandaag. Ik verwacht er wel wat van!

TheBiG 16 november 2020 08:24

Richard Sneller heeft zijn belang van 5.29% in ODX van de hand gedaan.
Date on which the threshold was crossed or reached was 13 november.

Prijsman 16 november 2020 09:08

Mooie opening! Eens kijken of we dit vol kunnen houden.

Prettige week toegewenst iedereen.

TheBiG 16 november 2020 12:43

Omega Diagnostics Q&A: ready to seize the significant opportunity ahead

It’s been a few months since we featured Omega Diagnostics in our going for growth series, eager to understand how the business has progressed since, we decided to briefly speak to Chief Executive Officer Colin King and get some direct questions answered amid an ever-changing landscape.

From broker targets to MHRA approvals and expected demand for COVID-19 testing, we put forward the key questions that our readers and ourselves were eager to know as Omega Diagnostics embarks on a potentially transformational year.

So without further ado, let’s get started:

1. How do you think news of the COVID-19 vaccine breakthrough alters the landscape for Omega Diagnostics over the coming months?
Omega welcomes the recent interim analysis re. the Pfizer/BioNTech COVID-19 vaccine candidate and news that we may be closer to an effective vaccine. Antibody testing, and the AbC-19 Rapid Test in particular, can play what the Company believes to be an instrumental role in assessing initial immune responses, and in determining where follow-up or booster campaigns may be needed.

The role of antibody testing is also likely to provide a long term use of the tests and given the number of vaccines worldwide presents a considerable opportunity.

2. Regarding the ABC-19 antibody tests, could you clarify that the MHRA approval is still in progress?
Yes, the process is ongoing and despite it taking longer than expected we still remain confident that we will receive approval.

Omega cannot comment further at this stage until a decision has been made, however, rest assured, when there is an update to me made Omega will announce news via RNS.

3. What opportunities are there to sell the ABC-19 antibody tests beyond the UK and will this generate better margins for Omega Diagnostics than with the UK RTC?
The Company is confident there is a significant opportunity to sell the ABC-19 antibody tests beyond the UK, due to product performance, and its link to the UK Government.

The consortium is actively looking at other markets across the world including the US and yes this will generate better margins.

All profits generated above the Government pricing will be shared equally amongst members.

4. You recently forecast production to scale to 2m lateral flow tests per week by April with the majority coming from ‘other’ rather than UK-RTC. Is this still on track and what does ‘other’ represent?
We remain on track to increase our capacity as outlined in the recent shareholder presentation. The other demand is forecast to be largely made up of Antigen tests however, CD4 and our own brand Antibody tests will also contribute to this overall demand. If you recall the rationale for building the capacity is that it could be adjusted based on demand.

For example, if early in the new year there is a greater requirement for antigen testing we will focus our efforts there but if antibody testing as a result of a vaccine requires greater capacity later in the year we can move capacity.

5. Brokers have struggled to put a target price on Omega Diagnostics in recent months. What do you think the barriers are to this and do you think it will become viable to do so soon?
finnCap’s price target is under review given the difficulty in forecasting revenues from COVID-19 antibody and antigen tests with any degree of accuracy. When that changes then we would expect finnCap to consider a target price.

That said, they have made it clear that even without firm forecasts or a target price the valuation upside is considered substantial and they have provided a very helpful assessment of potential revenues and gross profits at different utilisation rates in their note from 22 June 2020.

6. Let’s assume 1 year from now COVID-19 has come and gone. What’s the vision for where Omega Diagnostics will be?
Omega has a diversified portfolio of diagnostic tests including Food Intolerance and CD4 testing for HIV, as well as Covid, and is well funded and positioned to benefit from the opportunities and exist for growth globally though our established distribution partners.

As mentioned above we would expect on-going demand for the UK-RTC due to the vaccine to go beyond the one year window.

In addition with the CHAI initiative for CD4 on-going we would expect more countries to have adopted the advanced disease initiative and therefore drive increased sales.

www.sharebuyers.co.uk/shares/omega-di...

[verwijderd] 16 november 2020 13:28

www.ad.nl/binnenland/ook-moderna-komt...

börse.de 16 november 2020 22:05

Flinke Sof vandaag, na aanvankelijk een spectaculaire ochtend; moderna nieuws gooide roet in het eten ( ook bij NVCT); herstel komt; vaccineren en testen gaan hand in hand,

[verwijderd] 17 november 2020 11:26

Abbo

[verwijderd] 17 november 2020 12:22

twitter.com/Ahk910/status/13285974783...
twitter.com/Ahk910/status/13286058954...

[verwijderd] 17 november 2020 12:24

Lijkt alsof ODX FDA approval heeft?

TheBiG 17 november 2020 14:10

Yorkshire developed Covid-19 test approved for use in North America

A Covid-19 rapid antibody test, developed by York-based medical device manufacturer Abingdon Health, is to be used to detect this illness in the USA.

Abingdon has been notified by the US Food and Drug Administration (FDA) that it will now be able to distribute its UK-RTC AbC19™ Rapid Test in the USA to laboratories and to healthcare workers, for point of care testing.

Distribution of the test will be through CIGA Healthcare, a member of the UK-Rapid Test Consortium. (UK-RTC)

www.thebusinessdesk.com/yorkshire/new...

TheBiG 17 november 2020 14:14

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

UK-RTC Update

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the press release issued today by the UK Rapid Test Consortium ("UK-RTC"), of which Omega is a partner.

The UK-RTC press release announces that Abingdon Health ("Abingdon") has received confirmation from the US Food and Drug Administration ("FDA") that Abingdon has completed the notification process under the FDA's Policy for Coronavirus Disease Tests During the Public Health Emergency ("the Policy").

The Policy states that the FDA does not intend to object to a manufacturer distributing serology tests to laboratories that are certified under CLIA1 certification to perform high complexity testing where the test has been validated and while the manufacturer is preparing its Emergency Use Authorization ("EUA") request.

Abingdon has submitted an EUA to the FDA for the AbC-19™ Rapid Test as a point of care test and the Company looks forward to learning how the EUA procedure progresses.

A full copy of the UK-RTC press release is at the bottom of this announcement.

1 CLIA or the Clinical Laboratory Improvement Amendments (42 CFR Part 493) are those regulations that were established in 1988 for the regulation and quality assurance of human specimens within clinical laboratory environments.

[verwijderd] 17 november 2020 14:17

Maar de koers knalt onderuit desalniettemin?

[verwijderd] 17 november 2020 17:34

morgen hopelijk beter

[verwijderd] 17 november 2020 19:26

Geduld! Alles komt goed, de maan is soms niet zichtbaar maar dat wilt niet zeggen dat die niet binnen bereik is!

Wiz@rD 18 november 2020 10:47

Odx is weer stilletjes naar beneden aan het gaan. Ik denk niet ooit mijn gak van 95 te halen

[verwijderd] 18 november 2020 10:53

quote:
Wiz@rD schreef op 18 november 2020 10:47:
Odx is weer stilletjes naar beneden aan het gaan. Ik denk niet ooit mijn gak van 95 te halen

Waarom zou het nooit meer omhoog gaan?

[verwijderd] 18 november 2020 12:51

quote:
Wiz@rD schreef op 18 november 2020 10:47:
Odx is weer stilletjes naar beneden aan het gaan. Ik denk niet ooit mijn gak van 95 te halen

Ik heb voor de beeldvorming het koersverloop van ODX even naast die van Novacyt gelegd en de twee verschillen niet veel van elkaar. Sterker nog, het koersverloop is grotendeels gelijk.

imgur.com/a/bo91o8g

Wiz@rD 18 november 2020 14:04

Maar novacyt heeft al veel cash opgebouwd, odx zie ik hier minder van. Ook minder straf forum :-)

Fluxx 18 november 2020 22:45

ODX is zeker geen Novacyt. Echter is de waardering er ook niet naar. Huidige market cap is 93 miljoen. Een deal zoals nu rond gaat van 75 miljoen. Is direct bijna de hele beurswaarde.

Gaat dit aandeel nog naar de 0.95? Ja ik weet het zeker. De anti testen moeten de komende maanden gemaakt en verkocht worden. Twijfel je over je gak, en heb je de mogelijkheid. Verlaag m dan nu met de huidige aanbieding prijzen.

454 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 ... 19 20 21 22 23 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX	881,80	+7,01	+0,80%	14:29
AMX	931,55	-2,88	-0,31%	14:29
ASCX	1.208,53	+4,48	+0,37%	14:14
BEL 20	3.904,95	+14,24	+0,37%	14:29
Germany40^	18.175,80	+38,15	+0,21%	14:29
US30^	38.490,27	-14,69	-0,04%	14:29
US500^	5.083,63	+13,93	+0,27%	14:29
Nasd100^	17.593,36	+111,69	+0,64%	14:29
Japan225^	38.263,76	+325,05	+0,86%	14:28
WTI	82,98	-0,32	-0,38%	14:28
Brent	88,09	-0,20	-0,23%	14:28
EUR/USD	1,0688	-0,0014	-0,13%	14:29
BTC/USD	66.371,99	+39,30	+0,06%	12:39
Gold spot	2.315,69	-6,33	-0,27%	14:29